Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference

Rhea-AI Summary

Ovid Therapeutics Inc. (NASDAQ: OVID) announced that President and Chief Medical Officer Amit Rakhit, M.D., MBA, will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 19 at 1:20 p.m. ET. This session aims to discuss the company's commitment to developing transformative medicines for rare neurological diseases. Ovid's pipeline includes the investigational medicine OV101 for Angelman syndrome and Fragile X syndrome, and OV935 for rare developmental and epileptic encephalopathies in collaboration with Takeda. Details will be available through their website.

Positive

• Participation in a high-profile healthcare conference enhances visibility.
• Development of OV101 and OV935 shows commitment to addressing rare neurological diseases.

Negative

• None.

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on Tuesday, May 19, at 1:20 p.m. ET.

A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine^® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com/.

Contacts

Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
irpr@ovidrx.com

Or

Investors:
Steve Klass
Burns McClellan, Inc.
sklass@burnsmc.com
(212) 213-0006

Media:
Katie Engleman
1AB
katie@1abmedia.com
(919) 333-7722

FAQ

What conference will Ovid Therapeutics participate in on May 19, 2020?

Ovid Therapeutics will participate in the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 19, 2020.

Who is presenting for Ovid Therapeutics at the RBC conference?

Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will present for Ovid Therapeutics.

What is Ovid Therapeutics developing for neurological diseases?

Ovid Therapeutics is developing OV101 for Angelman syndrome and Fragile X syndrome, and OV935 for rare developmental and epileptic encephalopathies.

Where can I access the audio webcast of Ovid's conference presentation?

The audio webcast can be accessed through the Events & Presentations section of Ovid's website.